Zim laboratories promoter Zulfiqar Kamal has submitted a regulatory disclosure to stock exchanges declaring that no encumbrance of shares was made during the financial year ended March 31, 2026. The disclosure was filed on April 1, 2026, with both BSE Limited and National Stock Exchange of India Limited.

Regulatory Compliance Declaration

The disclosure was made pursuant to Regulation 31(4) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. In his formal declaration, Kamal stated that he, along with persons acting in concert, have not made any encumbrance of shares, either directly or indirectly, during the specified financial year.

Stock Exchange Notification

The disclosure was simultaneously submitted to multiple regulatory bodies and stakeholders. The communication was addressed to BSE Limited's Compliance Department and National Stock Exchange of India Limited's Listing Compliance Department. Additionally, the Audit Committee of ZIM Laboratories Limited was included in the disclosure process.

Promoter Declaration Scope

The declaration encompasses a comprehensive coverage of potential encumbrance activities. Kamal's statement specifically covers both direct and indirect encumbrances, ensuring complete transparency regarding share-related transactions. The disclosure also extends to include any persons acting in concert with the promoter, providing a broader scope of compliance coverage.

This regulatory filing demonstrates the company's commitment to maintaining transparency and adhering to SEBI's disclosure requirements for substantial shareholding and takeover regulations.

ZIM Laboratories Limited has made a strategic investment of Rs. 89.45 lakhs in its Australian subsidiary ZIMTAS Pty Ltd, as disclosed in a regulatory filing dated April 9, 2026. The investment represents a significant step in the company's international expansion strategy.

Investment Details

The pharmaceutical company has invested Rs. 89,45,100 (equivalent to AUD 1,35,000) in the equity shares of ZIMTAS Pty Ltd. This investment falls within the previously approved investment ceiling of up to Rs. 2.00 crores for the Australian subsidiary.

Shareholding Structure

Following this equity investment, ZIM Laboratories now holds 99.96% of the total share capital of ZIMTAS Pty Ltd, establishing near-complete ownership and control over the Australian entity. This substantial shareholding position strengthens the company's presence in the Australian market.

Regulatory Compliance

The disclosure was made in accordance with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company referenced previous intimations dated May 13, 2024, and July 2, 2024, indicating this investment was part of a planned strategic initiative.

Company Background

ZIM Laboratories Limited, operating under the motto "Zeal & Innovation in Medicine," continues to expand its international footprint through strategic investments. The company is listed on both BSE (Company Code: 541400) and NSE (Symbol: ZIMLAB), ensuring transparency in its corporate communications and regulatory disclosures.